Sector News

GlaxoSmithKline CEO: Chin up, investors. Dividend’s safe, and Novartis deal awaits

December 19, 2014
Life sciences
GlaxoSmithKline’s shareholders may be expecting less-than-stellar sales next year as generics take their toll on respiratory behemoth Advair. But they still have plenty to look forward to, CEO Andrew Witty reminded them on Thursday.
 
For starters, there’s the multibillion-dollar asset swap with Novartis that the companies announced in April. On Thursday, the British pharma’s investors approved the deal–which will send GSK’s oncology assets over to Switzerland and bring most of Novartis’ vaccines business over in return, as well as form a joint venture in consumer health–by an “overwhelming majority,” according to Reuters.
 
As Glaxo said in April, the transaction will up its annual revenue by £1.3 billion. And as Witty reiterated on Thursday, after next year’s slated deal close, the company will return £4 billion to shareholders, Bloomberg reports.
 
And despite rumors that the pharma giant would cut its dividend on its top-line struggles, Witty confirmed his company plans to maintain 2014’s dividend of 80 pence a share next year, remarking that investors shouldn’t be worried.
 
But considering Glaxo’s bleak sales picture as of late, it’s no surprise that some of them found pause for concern. Top product Advair plunged 25% last quarter, fueling a 12% pharmaceutical sales slide. And that’s only set to continue as copycats eat away at the one-time $8-billion-a-year seller; in preparation, the drugmaker this year initiated a $1.6 billion restructuring, which most recently claimed at least 900 sales and R&D jobs focused in Research Triangle Park, NC.
 
By Carly Helfand
 

Related News

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]